Long Non-Coding RNA (lncRNA) RAMS11 Promotes Metastatis and Cell Growth of Prostate Cancer by CBX4 Complex Binding to Top2α

References

• Jin W, Fei X, Wang X, Chen F, Song Y. Circulating miRNAs as biomarkers for prostate cancer diagnosis in subjects with benign prostatic hyperplasia. J Immunol Res. 2020;2020:5873056. doi:10.1155/2020/587305632455140
   PubMed Web of Science ®Google Scholar
• Ranasinghe WKB. Patterns of metastases of prostatic ductal adenocarcinoma. Mediators Inflamm. 2020.
   Google Scholar
• Fredsøe J, Kirkegaard P, Edwards A, Vedsted P, Sørensen KD, Bro F. A genetic risk assessment for prostate cancer influences patients’ risk perception and use of repeat PSA testing: a cross-sectional study in Danish general practice. BJGP Open. 2020;4(2):bjgpopen20X101039. doi:10.3399/bjgpopen20X101039
   PubMedGoogle Scholar
• Jin W. Detection and prognosis of prostate cancer using blood-based biomarkers. J Immunol Res. 2020;2020:8730608.
   Google Scholar
• Mahira S, Kommineni N, Husain GM, Khan W. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: a new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomed Pharmacother. 2019;110:803–817. doi:10.1016/j.biopha.2018.11.14530554119
   PubMed Web of Science ®Google Scholar
• Pessoa RR, Viana PC, Mattedi RL, et al. Value of 3-tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance. BJU Int. 2017;119:535–542. doi:10.1111/bju.1362427500389
   PubMed Web of Science ®Google Scholar
• Jiang N, Niu G, Pan YH, et al. CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma. EBioMedicine. 2020;53:102692. doi:10.1016/j.ebiom.2020.10269232113161
   PubMed Web of Science ®Google Scholar
• Pu Z, Che Y, Zhang W, et al. Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells. Int J Mol Med. 2019;43:2291–2302. doi:10.3892/ijmm.2019.415631017261
   PubMed Web of Science ®Google Scholar
• Milosevich N, McFarlane J, Gignac MC, et al. Pan-specific and partially selective dye-labeled peptidic inhibitors of the polycomb paralog proteins. Bioorg Med Chem. 2020;28(1):115176. doi:10.1016/j.bmc.2019.11517631753799
   PubMed Web of Science ®Google Scholar
• Wang S, Denton KE, Hobbs KF, Weaver T, McFarlane JMB. Optimization of ligands using focused DNA-encoded libraries to develop a selective, cell-permeable CBX8 chromodomain inhibitor. ACS Chem Biol. 2020;15:112–131. doi:10.1021/acschembio.9b0065431755685
   PubMed Web of Science ®Google Scholar
• Fang Y, Yang C, Zhang L, Wei L, Lin J. Spica prunellae extract enhances fluorouracil sensitivity of 5-fluorouracil-resistant human colon carcinoma HCT-8/5-FU cells via TOP2α and miR-494. Biomed Res Int. 2019;2019:5953619. doi:10.1155/2019/595361931662984
   PubMed Web of Science ®Google Scholar
• Kanagasabai R, Karmahapatra S, Kientz CA, et al. The novel C-terminal truncated 90-kDa isoform of topoisomerase IIα (TOP2α/90) is a determinant of etoposide resistance in K562 leukemia cells via heterodimerization with the TOP2α/170 isoform. Mol Pharmacol. 2018;93:515–525. doi:10.1124/mol.117.11156729514855
   PubMed Web of Science ®Google Scholar
• Zhao W, Jiang G, Bi C, et al. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation. Oncotarget. 2015;6:37871–37894. doi:10.18632/oncotarget.568026462155
   PubMedGoogle Scholar
• Duzcan F, Duzcan SE, Sen S, et al. Expression and amplification of topoisomerase-2α in type 1 and type 2 papillary renal cell carcinomas and its correlation with HER2/neu amplification. Pathol Oncol Res. 2011;17:697–703. doi:10.1007/s12253-011-9372-021461646
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-263428701486
   PubMed Web of Science ®Google Scholar
• Castro-Oropeza R, Melendez-Zajgla J, Maldonado V, Vazquez-Santillan K. The emerging role of lncRNAs in the regulation of cancer stem cells. Cell Oncol (Dordr). 2018;41:585–603. doi:10.1007/s13402-018-0406-430218296
   PubMed Web of Science ®Google Scholar
• Chang YN, Zhang K, Hu ZM, et al. Hypoxia-regulated lncRNAs in cancer. Cell Oncol (Dordr). 2016;575:1–8.
   Google Scholar
• Paparo F, Peirano A, Matos J, et al. Diagnostic value of retrospectively fused (64)CuCl(2) PET/MRI in biochemical relapse of prostate cancer: comparison with fused (18)F-Choline PET/MRI, (64)CuCl2 PET/CT, (18)F-Choline PET/CT, and mpMRI. Abdom Radiol (NY). 2020;45(11):3896–3906. doi:10.1007/s00261-020-02591-732451674
   PubMed Web of Science ®Google Scholar
• van Leenders G, van der Kwast TH, Grignon DJ, et al., ISUP Grading Workshop Panel Members. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2018;44(8):e87–e99. doi:10.1097/PAS.0000000000001497
   Web of Science ®Google Scholar
• Wu C, Jiang H, Chen J. A systematic review and meta-analysis about the effect of bisphosphonates on the risk of skeletal-related event in men with prostate cancer. Anticancer Agents Med Chem. 2020;20(13):1604–1612. doi:10.2174/187152062066620052111481532436834
   PubMed Web of Science ®Google Scholar
• Salles DC, Mata DA, Epstein JI. Significance of paneth-cell-like differentiation in prostatic adenocarcinoma: a retrospective cohort study of 80 cases. Hum Pathol. 2020;S0046–8177(20)30096–4.
   Web of Science ®Google Scholar
• Silva-Fisher JM, Dang HX, White NM, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11:2156. doi:10.1038/s41467-020-15547-832358485
   PubMed Web of Science ®Google Scholar
• Yerokun T, Winfield LL. LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2. Anticancer Res. 2014;34:4755–4759.25202054
   PubMed Web of Science ®Google Scholar
• Tan C, Bei C, Zhu X, Zhang Y, Qin L, Tan S. Single nucleotide polymorphisms of CBX4 and CBX7 decrease the risk of hepatocellular carcinoma. Biomed Res Int. 2019;2019:6436825. doi:10.1155/2019/643682531211140
   PubMed Web of Science ®Google Scholar
• Ferreira D, Soares M, Correia J, Adega F, Ferreira F, Chaves R. Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines. Aging. 2019;11(13):4688–4705. doi:10.18632/aging.10207931301170
   PubMedGoogle Scholar